Vseobecni Fakultni Nemocnice V Praze
- Address
- lock Available on a paid plan
Vseobecni Fakultni Nemocnice V Praze - Pediatric Rheumatology Research Center
Vseobecni Fakultni Nemocnice V Praze (General University Hospital in Prague) is a leading research institution specializing in pediatric rheumatological conditions. The center demonstrates particular expertise in investigating novel therapeutic approaches for complex juvenile idiopathic arthritis (JIA) subtypes in children and adolescents.
- Juvenile Psoriatic Arthritis clinical trials and advanced treatment protocols
- Enthesitis-Related Arthritis including Juvenile Onset Ankylosing Spondylitis research
- Biologic therapy evaluation and efficacy studies in pediatric populations
The research center actively participates in multinational clinical trials evaluating targeted biologic therapies such as ixekizumab for challenging JIA subtypes. Their research focuses on measuring therapeutic efficacy using established ACR response criteria, contributing valuable data to the understanding of inflammatory arthritis treatment in pediatric patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Vseobecni Fakultni Nemocnice V Praze
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Subcutaneous Ixekizumab Versus Adalimumab in Pediatric Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis | Eli Lilly & Co. | Phase III | Not Recruiting | Feb 2021 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adalimumab | 1 | Unknown | 2021-02-22 | 2021-02-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.